Endocrinology

DKA Knowledge Challenge!

Diabetic ketoacidosis isn’t just an emergency room concern. It can start with subtle signs you might see first in your patients. This quick quiz zeroes in on the key red flags, risk factors, and management essentials of DKA that every PCP should know. Test your knowledge and sharpen your clinical instincts - it could make all the difference.

Click here to participate in survey

Latest News

Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial
Once-Monthly Maridebart Cafraglutide Produces Up to 20% Weight Loss in Phase 2 Trial

June 26th 2025

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity   / image credit ©Viking Therapeutics
Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity

June 26th 2025

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase
Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

June 24th 2025

FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia / image credit ©pivovit/stock.adobe.com
FDA, EMA Grant Lu AG13909 Orphan Drug Status for Treatment of Congenital Adrenal Hyperplasia

June 24th 2025

 Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial / image credit American Diabetes Association
Bimagrumab + Semaglutide Highly Effective for Loss of Fat, Preservation of Muscle in Phase 2b BELIEVE Trial

June 24th 2025

Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.